Department of pharmaceutics, Kamla Nehru College of Pharmacy, Borkhedi Gate, Butibori, Nagpur, India-441108
Vestibular disorders, including vertigo, Meniere’s disease, and vestibular neuritis, represent a significant clinical burden due to their impact on balance, spatial orientation, and quality of life. Conventional pharmacotherapy is often limited by poor drug penetration across the blood–brain barrier (BBB), systemic side effects, and suboptimal therapeutic efficacy. In this context, nanonasal nose-to-brain (N2B) drug delivery has emerged as a promising non-invasive strategy for targeted central nervous system (CNS) delivery. The nasal cavity provides a unique anatomical pathway via olfactory and trigeminal nerves, enabling direct transport of drugs to the brain while bypassing the BBB.The integration of nanotechnology into intranasal delivery systems has further enhanced drug targeting efficiency by improving solubility, stability, permeability, and controlled release. Various nanocarriers, including lipid-based systems (liposomes, solid lipid nanoparticles, nanostructured lipid carriers), polymeric nanoparticles (PLGA, chitosan), and advanced platforms such as nanoemulsions, dendrimers, and exosomes, have demonstrated significant potential in preclinical studies. Formulation strategies such as mucoadhesion, surface modification, and in situ gel systems play a critical role in overcoming nasal physiological barriers and enhancing drug residence time.Comprehensive evaluation through in vitro, ex vivo, and in vivo studies has confirmed improved brain targeting efficiency, drug transport, and biodistribution profiles of nanonasal systems. Despite these advancements, challenges such as limited dose volume, mucociliary clearance, nanoparticle toxicity, and scale-up complexities remain. Future prospects involving stimuli-responsive nanocarriers, nanorobotics, and precision delivery systems are expected to further advance this field.Overall, nanonasal N2B delivery represents a cutting-edge approach with strong potential to revolutionize the treatment of vestibular disorders by enabling efficient, targeted, and patient-friendly drug delivery to the CNS
Vestibular disorders comprise a heterogeneous group of conditions affecting the inner ear and central nervous system (CNS) pathways responsible for maintaining balance and spatial orientation [1]. Among these, vertigo, Meniere’s disease, and vestibular neuritis are the most prevalent clinical conditions, significantly impairing patient quality of life [2]. Vertigo is characterized by a false sensation of motion, often associated with nausea and postural instability [3]. Meniere’s disease is a chronic, progressive disorder marked by episodic vertigo, fluctuating hearing loss, tinnitus, and aural fullness, primarily resulting from endolymphatic hydrops [4]. Vestibular neuritis, on the other hand, involves inflammation of the vestibular nerve, leading to acute onset dizziness and imbalance without auditory symptoms [5]. The increasing global burden of these disorders underscores the need for more effective and targeted therapeutic interventions [6].
Currently available pharmacological treatments, including antihistamines, benzodiazepines, anticholinergics, and corticosteroids, primarily provide symptomatic relief rather than addressing the underlying pathophysiology [7]. Moreover, these drugs are associated with several limitations such as sedation, cognitive impairment, dependency risks, and systemic adverse effects [8]. A major challenge in the treatment of vestibular disorders is the poor penetration of therapeutic agents across the blood–brain barrier (BBB), which significantly limits drug bioavailability at the target site [9]. Additionally, conventional routes of administration, including oral and parenteral delivery, often result in first-pass metabolism, reduced therapeutic efficiency, and frequent dosing requirements [10].
To overcome these challenges, targeted drug delivery to the CNS has become a major focus in pharmaceutical research. However, the BBB remains a formidable obstacle, restricting the entry of most drugs into the brain due to its highly selective permeability [11]. This has driven the exploration of alternative delivery routes capable of bypassing the BBB and ensuring direct access to the brain.
In this regard, nose-to-brain (N2B) delivery has emerged as a promising non-invasive approach for direct CNS targeting [12]. The nasal cavity provides a unique anatomical and physiological connection to the brain via the olfactory and trigeminal nerve pathways, allowing drugs to bypass the BBB and achieve rapid therapeutic concentrations in the CNS [13]. Intranasal delivery offers several advantages, including rapid onset of action, reduced systemic exposure, avoidance of first-pass metabolism, and improved patient compliance [14]. These attributes make N2B delivery particularly suitable for the management of neurological and vestibular disorders [15].
The incorporation of nanotechnology into intranasal delivery systems has further enhanced the potential of this approach. Nanocarriers such as polymeric nanoparticles, solid lipid nanoparticles, nanoemulsions, liposomes, and dendrimers have demonstrated the ability to improve drug solubility, stability, and permeability across biological membranes [16]. These nanosystems can facilitate targeted and controlled drug delivery to the brain, thereby enhancing therapeutic efficacy while minimizing systemic side effects [17]. Furthermore, surface modification strategies, including ligand conjugation and the use of mucoadhesive polymers such as chitosan, can improve nasal residence time and promote drug absorption through the nasal mucosa [18].
Recent advances in nanonasal drug delivery have shown promising results in preclinical and clinical studies for CNS disorders, including vestibular dysfunctions [19]. The ability of nanocarriers to protect drugs from enzymatic degradation and enable sustained release further contributes to improved pharmacokinetic and pharmacodynamic profiles [20].
In summary, nanonasal nose-to-brain delivery represents a novel and highly promising strategy for overcoming the limitations of conventional pharmacotherapy in vestibular disorders. This approach offers the potential for enhanced brain targeting, improved therapeutic outcomes, and reduced systemic toxicity, thereby paving the way for future advancements in the management of vestibular diseases.
2. Anatomy and Physiology of the Nasal Cavity
The nasal cavity plays a crucial role in facilitating direct drug transport to the brain and has therefore become a focal point in the development of nose-to-brain (N2B) delivery systems. Its unique anatomical and physiological features enable drugs to bypass the blood–brain barrier (BBB) and reach the central nervous system (CNS) through neuronal pathways [21].
2.1 Nasal Regions: Vestibular, Respiratory, and Olfactory
The human nasal cavity is anatomically divided into three distinct regions: the vestibular, respiratory, and olfactory regions, each with specific structural and functional characteristics [22].
The nasal vestibule, located at the anterior portion of the nasal cavity, is lined with stratified squamous epithelium and contains nasal hairs (vibrissae). This region primarily acts as a filtration barrier, trapping particulate matter and limiting drug absorption, making it less relevant for systemic or CNS drug delivery [23].
The respiratory region constitutes the largest portion of the nasal cavity and is lined with pseudostratified ciliated columnar epithelium. It is highly vascularized and plays a major role in systemic drug absorption due to its large surface area and rich blood supply [24]. However, drug delivery through this region mainly results in systemic circulation rather than direct brain targeting.
The olfactory region, located in the upper posterior part of the nasal cavity, is of particular importance for N2B delivery. It is lined with specialized olfactory epithelium containing olfactory receptor neurons, supporting cells, and basal cells [25]. This region provides a direct anatomical connection between the external environment and the brain, making it the primary target for CNS drug delivery via the intranasal route.
2.2 Olfactory Epithelium and Trigeminal Nerve Pathways
Drug transport from the nasal cavity to the brain occurs primarily through two neural pathways: the olfactory and trigeminal pathways [26].
The olfactory pathway involves the uptake of drug molecules by olfactory receptor neurons, followed by their transport along axons to the olfactory bulb and subsequently to other brain regions [27]. This pathway allows for both intracellular (axonal transport) and extracellular (paracellular diffusion) mechanisms of drug delivery.
The trigeminal nerve pathway provides an additional route for drug transport to the brainstem and other CNS regions. The trigeminal nerve innervates both the respiratory and olfactory regions of the nasal cavity, enabling drug molecules to reach deeper brain structures, including areas associated with vestibular processing [28].
Together, these pathways facilitate rapid and direct drug delivery to the CNS, bypassing the BBB and enhancing therapeutic efficacy.
2.3 Mucociliary Clearance and Enzymatic Barriers
Despite its advantages, intranasal drug delivery faces several physiological barriers that can limit drug absorption and bioavailability. One of the primary challenges is mucociliary clearance, a defense mechanism in which mucus and entrapped particles are transported toward the nasopharynx and subsequently swallowed [29]. This process significantly reduces the residence time of drugs in the nasal cavity, thereby limiting their absorption.
Additionally, the nasal mucosa contains various enzymatic barriers, including cytochrome P450 enzymes, proteases, and peptidases, which can degrade drug molecules before they reach the brain [30]. These enzymatic activities are particularly problematic for peptide and protein-based therapeutics. Other barriers include tight junctions between epithelial cells, which restrict paracellular transport, and the presence of mucus layers that can impede drug diffusion [31]. These factors collectively necessitate the use of advanced delivery systems, such as nanocarriers and mucoadhesive formulations, to enhance drug retention and absorption.
2.4 Relevance to Vestibular System Targeting
The anatomical and physiological characteristics of the nasal cavity make it highly suitable for targeting the vestibular system through N2B delivery. The vestibular nuclei, located in the brainstem, can be accessed via trigeminal nerve pathways, while higher vestibular processing centers can be reached through olfactory connections [32].
Intranasal delivery enables rapid transport of therapeutic agents to these regions, which is particularly beneficial in acute conditions such as vertigo and vestibular neuritis. Moreover, the ability to bypass systemic circulation reduces off-target effects and enhances drug concentration at the site of action.
The integration of nanotechnology further improves targeting efficiency by enhancing drug permeability, protecting against enzymatic degradation, and prolonging nasal residence time [33]. As a result, nanonasal N2B delivery systems hold significant promise for improving therapeutic outcomes in vestibular disorders.
Table 1. Comparison of Nanocarriers for Nanonasal Nose-to-Brain Delivery
|
Nanocarrier Type |
Composition |
Advantages |
Limitations |
Suitability for N2B Delivery |
|
Liposomes |
Phospholipid bilayer vesicles |
Biocompatible, dual drug loading (hydrophilic + lipophilic), enhances permeability |
Stability issues, leakage |
Good |
|
Solid Lipid Nanoparticles (SLNs) |
Solid lipids + surfactants |
Controlled release, good stability, protects drug |
Low drug loading, drug expulsion |
Good |
|
Nanostructured Lipid Carriers (NLCs) |
Solid + liquid lipids |
High drug loading, improved stability, reduced leakage |
Complex formulation |
Excellent |
|
PLGA Nanoparticles |
Biodegradable polymer (PLGA) |
Sustained release, FDA-approved, tunable degradation |
Cost, slower drug release |
Excellent |
|
Chitosan Nanoparticles |
Natural polymer (chitosan) |
Mucoadhesive, enhances permeability, opens tight junctions |
Limited mechanical strength |
Excellent |
|
Nanoemulsions |
Oil-water dispersions |
Improves solubility, rapid absorption |
Stability depends on surfactant |
Good |
|
Dendrimers |
Branched polymers |
Precise structure, high drug loading |
Toxicity concerns |
Moderate |
|
Metallic Nanoparticles |
Gold, silver |
High surface area, imaging capability |
Toxicity, accumulation risk |
Limited |
|
Exosomes |
Natural vesicles |
Biocompatible, low immunogenicity, BBB crossing |
Isolation complexity |
Excellent |
3. Pathophysiology of Vestibular Disorders
3.1 Structure and Function of the Vestibular System
The vestibular system is a complex sensory apparatus responsible for maintaining balance, posture, and spatial orientation. It comprises peripheral and central components that work in coordination to detect head movements and stabilize vision [34].
The peripheral vestibular system, located within the inner ear, consists of the semicircular canals, utricle, and saccule. The semicircular canals detect angular acceleration, while the otolithic organs (utricle and saccule) sense linear acceleration and gravitational forces [35]. These structures contain specialized hair cells that transduce mechanical stimuli into neural signals.
The central vestibular system includes the vestibular nuclei in the brainstem and their connections to the cerebellum, thalamus, and cerebral cortex [36]. The vestibular nuclei integrate sensory inputs from the inner ear, visual system, and proprioceptors to maintain equilibrium and coordinate eye and body movements. The vestibulo-ocular reflex (VOR) is a critical function that stabilizes gaze during head motion [37].
Proper functioning of this system is essential for maintaining balance and coordinated movement. Any disruption in these pathways can lead to symptoms such as dizziness, vertigo, imbalance, and nausea.
3.2 Etiology: Inflammation, Infection, and Neurodegeneration
Vestibular disorders arise from a variety of etiological factors, including inflammation, infection, and neurodegenerative processes [38].
Inflammatory conditions, such as vestibular neuritis, are often associated with viral infections that lead to inflammation of the vestibular nerve, resulting in acute vertigo and imbalance [39]. Infectious causes may include viral pathogens such as herpes simplex virus or bacterial infections affecting the inner ear, which can disrupt normal vestibular function [40]. These infections can damage hair cells or neural pathways, leading to persistent vestibular dysfunction.
Neurodegenerative changes also contribute to vestibular disorders, particularly in aging populations. Degeneration of vestibular hair cells, neuronal loss in vestibular pathways, and reduced central processing capacity can impair balance and increase the risk of falls [41]. Additionally, conditions such as Parkinson’s disease and multiple sclerosis are associated with vestibular dysfunction due to central nervous system involvement [42].
Meniere’s disease represents a multifactorial condition involving endolymphatic hydrops, where abnormal fluid accumulation in the inner ear leads to episodic vestibular symptoms [43]. Overall, the diverse etiologies of vestibular disorders complicate their diagnosis and treatment.
3.3 Current Therapeutic Challenges
Despite advances in pharmacotherapy, the management of vestibular disorders remains challenging due to several limitations. One of the primary issues is poor drug penetration into the CNS, largely attributed to the restrictive nature of the blood–brain barrier (BBB) [44]. Many therapeutic agents fail to reach effective concentrations at the vestibular nuclei and associated brain regions, resulting in suboptimal treatment outcomes.
Another major concern is the occurrence of systemic side effects associated with commonly used medications. Drugs such as antihistamines and benzodiazepines can cause sedation, cognitive impairment, and dependency, limiting their long-term use [45]. Anticholinergic agents may lead to dry mouth, blurred vision, and urinary retention, further reducing patient compliance. Additionally, current treatments are primarily symptomatic rather than disease-modifying, focusing on relieving vertigo and nausea rather than addressing the underlying pathology [46]. This often results in recurrence of symptoms and chronic disease progression.
Frequent dosing, variable bioavailability, and first-pass metabolism associated with oral administration further complicate therapy [47]. These challenges highlight the need for innovative drug delivery approaches that can enhance CNS targeting, reduce systemic exposure, and improve therapeutic efficacy.
4. Concept of Nose-to-Brain Drug Delivery
4.1 Mechanisms of Nose-to-Brain Transport
Intranasal drug delivery enables direct transport of therapeutic agents from the nasal cavity to the brain through multiple pathways, broadly categorized into intracellular, extracellular, and systemic mechanisms [48]. These pathways collectively facilitate efficient bypass of the blood–brain barrier (BBB) and enhance central nervous system (CNS) drug delivery.
4.1.1 Intracellular Pathway (Neuronal Transport)
The intracellular pathway involves the uptake of drug molecules into olfactory receptor neurons or trigeminal nerve endings, followed by axonal transport to various brain regions [49]. This process occurs via endocytosis or pinocytosis, where drug-loaded carriers are internalized into neuronal cells and transported along microtubules.
Although this mechanism provides targeted delivery, it is generally considered a relatively slow process, as axonal transport may take several hours to days depending on the distance and neuronal pathway involved [50]. However, it plays a crucial role in delivering macromolecules, peptides, and nanoparticle-based formulations that cannot easily diffuse through extracellular pathways.
4.1.2 Extracellular Pathway (Perineural Diffusion)
The extracellular pathway, also known as perineural or paracellular transport, involves the movement of drug molecules along the intercellular spaces and perineural channels surrounding olfactory and trigeminal nerves [51]. This pathway allows rapid diffusion of drugs directly into the brain and cerebrospinal fluid (CSF).
Compared to intracellular transport, extracellular diffusion is significantly faster and is considered the dominant mechanism for small molecules and certain nanocarriers [52]. It enables drugs to reach the olfactory bulb and brainstem within minutes of intranasal administration, making it highly advantageous for conditions requiring rapid therapeutic action.
4.1.3 Systemic Pathway
In addition to direct nose-to-brain transport, a portion of the administered drug may be absorbed into the systemic circulation through the highly vascularized respiratory region of the nasal cavity [53]. From there, the drug can reach the brain via the bloodstream, although this route is subject to BBB limitations.
While the systemic pathway contributes to overall drug distribution, it is generally less efficient for CNS targeting compared to direct neuronal pathways. Moreover, it may increase the risk of systemic side effects and reduce drug availability at the target site [54].
4.2 Advantages over Oral and Parenteral Routes
Intranasal N2B delivery offers several significant advantages over conventional oral and parenteral routes, particularly in the treatment of CNS and vestibular disorders.
4.2.1 Bypass of the Blood–Brain Barrier
One of the most important advantages is the ability to bypass the BBB, which is a major obstacle in CNS drug delivery [55]. Intranasal administration allows drugs to directly access the brain via olfactory and trigeminal pathways, thereby enhancing drug concentration at the target site and improving therapeutic efficacy.
4.2.2 Rapid Onset of Action
N2B delivery enables rapid drug transport to the brain, often within minutes, due to the direct connection between the nasal cavity and CNS [56]. This is particularly beneficial in acute conditions such as vertigo attacks and vestibular neuritis, where immediate symptom relief is required.
4.2.3 Reduced Systemic Exposure and Side Effects
Intranasal delivery minimizes systemic drug exposure by targeting the CNS directly, thereby reducing the risk of peripheral side effects [57]. This is especially advantageous for drugs like benzodiazepines and antihistamines, which are associated with sedation and other systemic adverse effects when administered orally or intravenously.
4.2.4 Avoidance of First-Pass Metabolism
Unlike oral administration, intranasal delivery bypasses hepatic first-pass metabolism, leading to improved bioavailability and reduced dose requirements [58]. This enhances the overall efficiency of drug therapy.
4.2.5 Improved Patient Compliance
The non-invasive nature of intranasal delivery improves patient acceptability and compliance, particularly in chronic conditions requiring long-term treatment [59]. It eliminates the need for injections and reduces dosing frequency when combined with sustained-release formulations.
5. Role of Nanotechnology in N2B Delivery
5.1 Need for Nanocarriers
The successful delivery of therapeutic agents to the central nervous system (CNS) via the intranasal route is often limited by several physicochemical and biological challenges. Many drugs used in the management of vestibular disorders exhibit poor aqueous solubility, low permeability across biological membranes, and instability in physiological environments [60]. These limitations significantly reduce drug bioavailability and therapeutic efficacy.
Additionally, drugs administered intranasally are exposed to enzymatic degradation within the nasal mucosa and are rapidly cleared by mucociliary mechanisms, leading to reduced residence time and absorption [61]. Furthermore, achieving effective drug concentrations at specific CNS targets, such as the vestibular nuclei, remains a major challenge due to diffusion barriers and limited targeting capability [62].
Nanocarriers have emerged as an advanced drug delivery platform capable of overcoming these limitations. By incorporating drugs into nanoscale systems (typically 10–200 nm), it is possible to enhance solubility, protect drugs from degradation, and facilitate targeted delivery to the brain [63]. Moreover, nanocarriers can be engineered with surface modifications, such as ligand attachment or mucoadhesive polymers, to improve interaction with the nasal mucosa and enhance transport through olfactory and trigeminal pathways [64].
5.2 Advantages of Nanocarriers
5.2.1 Enhanced Permeability
Nanocarriers significantly improve drug permeability across the nasal epithelium and neuronal pathways. Due to their small size and large surface area, nanoparticles can interact more efficiently with biological membranes and facilitate transcellular and paracellular transport [65].
Certain nanocarriers, such as those coated with chitosan or other mucoadhesive polymers, can transiently open tight junctions between epithelial cells, further enhancing drug absorption [66]. This property is particularly beneficial for delivering hydrophilic drugs and macromolecules that would otherwise exhibit poor permeability.
5.2.2 Controlled and Sustained Release
One of the key advantages of nanocarrier systems is their ability to provide controlled and sustained drug release. By modifying the composition and structure of the carrier (e.g., polymeric matrix, lipid composition), drug release kinetics can be precisely regulated [67].
This sustained release profile helps maintain therapeutic drug concentrations in the CNS over an extended period, reducing dosing frequency and improving patient compliance. It also minimizes fluctuations in drug levels, thereby enhancing therapeutic outcomes in chronic vestibular conditions [68].
5.2.3 Protection from Degradation
Nanocarriers offer significant protection against enzymatic and chemical degradation in the nasal cavity. Encapsulation of drugs within nanoparticles shields them from nasal enzymes such as proteases and cytochrome P450 enzymes, thereby preserving drug integrity [69].
This protective effect is especially important for sensitive molecules such as peptides, proteins, and nucleic acids, which are highly susceptible to degradation in biological environments [70]. As a result, nanocarriers enhance the stability and bioavailability of therapeutic agents.
6. Types of Nanocarriers Used
Nanocarriers used in intranasal drug delivery can be broadly classified into lipid-based, polymeric, and other advanced nanosystems. Each system offers unique advantages in terms of drug loading, stability, permeability, and targeting efficiency [71].
6.1 Lipid-Based Systems
Lipid-based nanocarriers are among the most widely explored systems for nose-to-brain delivery due to their biocompatibility, ability to encapsulate both hydrophilic and lipophilic drugs, and enhanced interaction with biological membranes [72].
6.1.1 Liposomes
Liposomes are spherical vesicles composed of phospholipid bilayers enclosing an aqueous core. They are capable of encapsulating both hydrophilic drugs (in the core) and lipophilic drugs (within the bilayer) [73].
Liposomes enhance drug permeation across nasal mucosa and provide protection against enzymatic degradation. Their structural similarity to biological membranes facilitates fusion with cell membranes, improving drug delivery to the brain [74]. However, limitations such as stability issues and potential drug leakage need to be addressed through formulation optimization.
6.1.2 Solid Lipid Nanoparticles (SLNs)
Solid lipid nanoparticles are composed of solid lipids stabilized by surfactants. They offer advantages such as controlled drug release, improved stability, and protection of labile drugs [75].
SLNs enhance nasal absorption and prolong drug residence time, making them suitable for CNS targeting. However, their relatively low drug loading capacity and potential for drug expulsion during storage are considered limitations [76].
6.1.3 Nanostructured Lipid Carriers (NLCs)
Nanostructured lipid carriers are second-generation lipid nanoparticles composed of a mixture of solid and liquid lipids. This combination creates an imperfect lipid matrix, allowing higher drug loading and reduced drug expulsion compared to SLNs [77].
NLCs provide improved stability, controlled release, and enhanced permeability, making them highly suitable for intranasal brain delivery applications [78].
6.2 Polymeric Systems
Polymeric nanoparticles are widely used due to their versatility, controlled release properties, and ability to be functionalized for targeted delivery [79].
6.2.1 PLGA Nanoparticles
Poly(lactic-co-glycolic acid) (PLGA) nanoparticles are biodegradable and biocompatible systems approved for pharmaceutical use. They provide sustained drug release and protection from degradation [80].
PLGA nanoparticles can be engineered for targeted delivery by modifying surface properties, thereby enhancing transport through olfactory and trigeminal pathways [81]. Their controlled degradation profile makes them particularly useful for chronic conditions.
6.2.2 Chitosan Nanoparticles
Chitosan-based nanoparticles are highly advantageous due to their mucoadhesive properties and ability to transiently open tight junctions in the nasal epithelium [82]. These properties enhance drug absorption and prolong nasal residence time. Additionally, chitosan is biocompatible and biodegradable, making it suitable for intranasal applications [83]. Chitosan nanoparticles are particularly effective for delivering peptides and hydrophilic drugs.
6.3 Other Nanocarrier Systems
6.3.1 Nanoemulsions
Nanoemulsions are thermodynamically stable dispersions of oil and water stabilized by surfactants, with droplet sizes in the nanometer range [84].They improve drug solubility and permeability and facilitate rapid absorption through the nasal mucosa. Their ease of preparation and scalability make them attractive for pharmaceutical applications [85].
6.3.2 Dendrimers
Dendrimers are highly branched, tree-like polymers with well-defined structures and multiple surface functional groups [86].These systems allow precise control over drug loading and targeting. Surface modification of dendrimers can enhance interaction with nasal mucosa and improve CNS delivery efficiency [87].
6.3.3 Metallic Nanoparticles
Metallic nanoparticles, such as gold and silver nanoparticles, have been explored for their unique physicochemical properties, including high surface area and ease of functionalization [88].They can be used for targeted drug delivery and imaging applications. However, concerns regarding toxicity and long-term safety limit their widespread use in clinical applications [89].
6.3.4 Exosomes
Exosomes are naturally occurring extracellular vesicles secreted by cells, playing a key role in intercellular communication [90].They have emerged as promising nanocarriers due to their inherent biocompatibility, low immunogenicity, and ability to cross biological barriers, including the BBB. Exosomes can be engineered to deliver drugs, proteins, or nucleic acids directly to the brain [91].
7. Formulation Strategies for Nanonasal Delivery
Efficient nose-to-brain (N2B) delivery requires careful formulation design to overcome nasal physiological barriers and enhance drug transport to the central nervous system (CNS). Advanced strategies such as mucoadhesion, surface modification, particle size optimization, and in situ gel systems play a critical role in improving therapeutic outcomes [92].
7.1 Mucoadhesive Systems (Chitosan, Carbopol)
Mucoadhesive systems are widely employed to enhance the residence time of formulations within the nasal cavity, thereby improving drug absorption [93]. The rapid mucociliary clearance mechanism typically limits drug contact time with the nasal epithelium, reducing bioavailability.
Polymers such as chitosan and carbopol exhibit strong mucoadhesive properties by interacting with mucin through electrostatic interactions and hydrogen bonding [94]. Chitosan, a cationic polymer, can transiently open tight junctions between epithelial cells, enhancing paracellular drug transport [95].
Carbopol, a synthetic polymer, increases formulation viscosity and adhesion to the nasal mucosa, thereby prolonging drug retention [96]. These systems not only improve drug absorption but also enhance permeability and stability, making them highly suitable for intranasal delivery.
7.2 Surface Modification (PEGylation, Ligand Targeting)
Surface modification of nanocarriers is an effective strategy to enhance targeting efficiency and improve pharmacokinetic profiles [97].
PEGylation (attachment of polyethylene glycol chains) is commonly used to increase nanoparticle stability, reduce aggregation, and prolong circulation time by minimizing recognition by the immune system [98]. In the context of intranasal delivery, PEGylation also helps improve mucus penetration and drug diffusion.
Ligand targeting involves conjugating specific ligands (e.g., peptides, antibodies, or sugars) onto the surface of nanoparticles to facilitate receptor-mediated uptake [99]. This approach enables selective targeting of neuronal cells and enhances transport through olfactory and trigeminal pathways, thereby improving brain delivery efficiency.
7.3 Particle Size Optimization (<200 nm)
Particle size is a critical parameter influencing the efficiency of nose-to-brain delivery. Nanoparticles with a size below 200 nm are generally considered optimal for intranasal administration [100].
Smaller particles exhibit improved diffusion through mucus layers and enhanced uptake by epithelial and neuronal cells [101]. They can more effectively traverse tight junctions and perineural pathways, facilitating rapid transport to the brain.
However, extremely small particles may be rapidly cleared or diffuse into systemic circulation, while larger particles (>200 nm) may exhibit limited permeability [102]. Therefore, careful optimization of particle size is essential to balance retention, absorption, and targeting efficiency.
7.4 In Situ Gels and Nano-Loaded Hydrogels
In situ gel systems are advanced formulations that undergo a soul-to-gel transition upon administration into the nasal cavity, triggered by physiological conditions such as temperature, pH, or ionic strength [103].
These systems enhance nasal residence time, reduce drug leakage, and provide sustained release of the encapsulated drug. When combined with nanocarriers, nano-loaded hydrogels offer dual advantages of controlled release and improved targeting [104].
For example, nanoparticles embedded within thermoresponsive or ion-sensitive gels can remain in the nasal cavity for extended periods, allowing gradual drug release and enhanced absorption through olfactory pathways [105]. This approach significantly improves bioavailability and therapeutic efficacy.
Table 3. Advantages of Nanonasal Delivery Over Conventional Routes
|
Parameter |
Oral Route |
Parenteral Route |
Nanonasal N2B Delivery |
|
BBB penetration |
Poor |
Limited |
Direct bypass |
|
First-pass metabolism |
Present |
Absent |
Absent |
|
Onset of action |
Slow |
Moderate |
Rapid |
|
Systemic side effects |
High |
Moderate |
Low |
|
Patient compliance |
High |
Low |
High |
|
Target specificity |
Low |
Moderate |
High |
8. Evaluation and Characterization
Comprehensive evaluation of nanonasal formulations is essential to ensure their efficiency, stability, and targeting capability for CNS delivery. These evaluations are typically categorized into in vitro, ex vivo, and in vivo studies, each providing critical insights into formulation performance [106].
8.1 In Vitro Studies
8.1.1 Particle Size, Polydispersity Index (PDI), and Zeta Potential
Particle size is a crucial parameter influencing nasal permeation and brain targeting efficiency. Nanoparticles with sizes below 200 nm are generally preferred for optimal transport across nasal epithelium and neuronal pathways [107].
The polydispersity index (PDI) indicates the uniformity of particle size distribution. A PDI value below 0.3 suggests a homogeneous system, which is desirable for reproducible performance [108].
Zeta potential reflects the surface charge of nanoparticles and is an important indicator of colloidal stability. Values typically greater than ±30 mV indicate good stability due to electrostatic repulsion, preventing aggregation [109]. Additionally, positively charged particles may enhance interaction with negatively charged nasal mucosa, improving mucoadhesion.
8.1.2 Drug Release Kinetics
In vitro drug release studies are conducted to evaluate the release profile of the drug from nanocarriers. These studies help determine whether the formulation provides immediate, sustained, or controlled release [110].Release kinetics are often analyzed using mathematical models such as zero-order, first-order, Higuchi, and Korsmeyer–Peppas models to understand the mechanism of drug release [111]. Controlled release behavior is particularly beneficial for maintaining therapeutic drug concentrations in the CNS over extended periods.
8.2 Ex Vivo Studies
8.2.1 Nasal Mucosa Permeation
Ex vivo permeation studies are typically performed using excised animal nasal mucosa (e.g., sheep, goat, or porcine) to evaluate drug transport across the nasal epithelium [112].
Franz diffusion cells are commonly used for these studies, where the formulation is applied to the donor compartment and permeation is measured over time [113]. Key parameters such as permeation coefficient, flux, and drug retention in the tissue are determined. These studies provide valuable insights into the formulation’s ability to overcome nasal barriers and predict in vivo performance.
8.3 In Vivo Studies
8.3.1 Brain Targeting Efficiency (DTE, DTP)
In vivo studies are essential to evaluate the actual brain-targeting capability of intranasal formulations. Two important parameters used are Drug Targeting Efficiency (DTE%) and Direct Transport Percentage (DTP%) [114].
These parameters provide quantitative evidence of the effectiveness of N2B delivery systems in bypassing the blood–brain barrier.
8.3.2 Biodistribution Studies
Biodistribution studies involve analyzing the distribution of the drug across various organs, including the brain, blood, liver, and kidneys, following administration [115].
These studies are typically conducted using animal models and may involve techniques such as fluorescence imaging, radiolabeling, or high-performance liquid chromatography (HPLC).
The primary objective is to confirm enhanced drug accumulation in the brain while minimizing systemic exposure. A successful nanonasal formulation should demonstrate higher brain drug concentration with reduced distribution to non-target organs [116].
9. Applications in Vestibular Disorders
Nanonasal nose-to-brain (N2B) delivery systems have demonstrated significant potential in improving the therapeutic management of vestibular disorders by enabling targeted delivery of drugs to the central nervous system (CNS). Various drug classes have been explored using this approach, supported by promising preclinical and experimental studies [117].
9.1 Drug Candidates for Nanonasal Delivery
9.1.1 Antiemetics (e.g., Ondansetron)
Antiemetic agents such as ondansetron are widely used to manage nausea and vomiting associated with vertigo and vestibular dysfunction [118]. However, conventional administration routes often result in delayed onset and systemic side effects.
Intranasal nanocarrier-based delivery of ondansetron has been shown to enhance brain uptake, improve bioavailability, and provide rapid symptomatic relief. Nanoformulations such as nanoemulsions and polymeric nanoparticles facilitate efficient transport through olfactory pathways, bypassing the blood–brain barrier (BBB) [119].
9.1.2 Antihistamines
Antihistamines (e.g., meclizine, dimenhydrinate) are commonly prescribed for vertigo management due to their vestibular suppressant effects [120]. Nanonasal delivery of antihistamines can reduce systemic exposure and associated side effects such as sedation and drowsiness. Enhanced permeability and targeted delivery to vestibular nuclei improve therapeutic outcomes compared to conventional oral administration [121].
9.1.3 Corticosteroids
Corticosteroids are used in conditions such as vestibular neuritis and Meniere’s disease due to their anti-inflammatory properties [122]. Intranasal nanoformulations of corticosteroids can enhance drug delivery to inflamed vestibular pathways while minimizing systemic adverse effects. Lipid-based nanocarriers and polymeric nanoparticles have shown improved retention and sustained release in nasal tissues [123].
9.1.4 Neuroprotective Agents
Neuroprotective agents, including antioxidants and neurotrophic factors, are being investigated for their potential to prevent or reverse neuronal damage in vestibular disorders [124].Nanonasal delivery enables direct transport of these agents to the brain, improving their therapeutic efficacy. Encapsulation within nanoparticles protects these sensitive molecules from degradation and enhances their stability and bioavailability [125].
9.2 Case Studies (Preclinical/Animal Studies)
Several preclinical studies have demonstrated the effectiveness of nanonasal delivery systems in enhancing brain targeting and therapeutic outcomes. For instance, intranasal administration of drug-loaded nanoparticles in animal models has shown significantly higher drug concentrations in the brain compared to intravenous or oral routes [126]. Studies involving nanoemulsions and chitosan-based nanoparticles have reported improved nasal permeation, prolonged residence time, and enhanced CNS delivery [127].
In rodent models, nanocarrier-based formulations have demonstrated increased drug accumulation in the olfactory bulb and brainstem regions, which are critical for vestibular processing [128]. These findings highlight the potential of nanonasal systems in achieving efficient and targeted drug delivery.
9.3 Potential for Targeted Inner Ear and Brainstem Delivery
The anatomical proximity of the nasal cavity to the CNS provides a unique opportunity for targeting both the inner ear and brainstem regions, which are central to vestibular function [129]. Drug delivery via trigeminal nerve pathways enables direct access to the brainstem, where vestibular nuclei are located. Similarly, olfactory pathways facilitate transport to higher brain centers involved in balance and spatial orientation [130].
Nanocarriers further enhance this targeting capability by improving drug permeability, prolonging residence time, and enabling controlled release. This targeted approach not only increases therapeutic efficacy but also reduces systemic exposure and adverse effects [131].
10. Challenges, Regulatory Aspects, and Future Prospects
10.1 Challenges in Nanonasal Nose-to-Brain Delivery
Despite significant advancements, nanonasal nose-to-brain (N2B) delivery systems face several limitations that hinder their widespread clinical application.
10.1.1 Limited Dose Volume
One of the primary constraints of intranasal drug delivery is the limited administration volume, typically ranging from 100–200 µL per nostril [132]. This restricts the total amount of drug that can be delivered, posing challenges for drugs requiring higher therapeutic doses. Formulation strategies must therefore focus on maximizing drug loading and efficiency within this confined volume.
10.1.2 Mucociliary Clearance
Rapid mucociliary clearance significantly reduces the residence time of formulations in the nasal cavity, leading to decreased drug absorption [133]. This physiological defense mechanism transports mucus and entrapped particles toward the nasopharynx, resulting in drug loss. Although mucoadhesive systems can partially overcome this limitation, complete prevention remains challenging.
10.1.3 Toxicity of Nanoparticles
The potential toxicity of nanocarriers is a critical concern in the development of intranasal delivery systems [134]. Factors such as particle size, surface charge, composition, and accumulation in tissues can influence toxicity profiles. Metallic nanoparticles and certain synthetic polymers may induce oxidative stress, inflammation, or cytotoxicity, necessitating thorough safety evaluation.
10.1.4 Reproducibility Issues
Achieving consistent and reproducible formulation characteristics remains a significant challenge [135]. Variability in particle size, drug loading, and release profiles can impact therapeutic performance. Additionally, differences in nasal physiology among individuals may lead to inconsistent drug absorption and efficacy.
10.2 Regulatory Considerations
10.2.1 Safety Evaluation
Regulatory approval of nanonasal formulations requires comprehensive safety and toxicity assessment, including evaluation of local nasal irritation, systemic toxicity, immunogenicity, and long-term effects [136].
Both in vitro and in vivo studies are essential to establish the safety profile of nanocarriers. Regulatory agencies emphasize the need for detailed characterization of nanoparticle properties, including size, surface chemistry, and biodegradability.
10.2.2 Scale-Up Challenges
The transition from laboratory-scale formulation to industrial production presents significant scale-up challenges [137]. Maintaining consistency in particle size distribution, drug loading, and stability during large-scale manufacturing is complex.Additionally, issues related to cost-effectiveness, reproducibility, and quality control must be addressed to ensure successful commercialization. Advanced manufacturing techniques and standardization protocols are required to overcome these barriers.
10.3 Future Prospects
10.3.1 Smart Nanocarriers (Stimuli-Responsive Systems)
Emerging stimuli-responsive nanocarriers represent a promising advancement in targeted drug delivery [138]. These systems can respond to specific physiological triggers such as pH, temperature, or enzymatic activity, enabling controlled and site-specific drug release.Such smart systems have the potential to enhance therapeutic precision and minimize off-target effects in CNS disorders.
10.3.2 Nanorobotics and Precision Delivery
The integration of nanorobotics into drug delivery systems is an exciting future direction. Nanorobots capable of navigating biological environments and delivering drugs to specific target sites could revolutionize CNS therapy [139]. Although still in early stages of development, this technology holds immense potential for achieving highly precise and efficient drug delivery to vestibular pathways.
10.3.3 Clinical Translation and Commercialization
Despite promising preclinical outcomes, clinical translation of nanonasal delivery systems remains limited [140]. Challenges such as regulatory hurdles, scalability, cost, and long-term safety must be addressed before widespread adoption. However, continued advancements in nanotechnology, formulation strategies, and regulatory frameworks are expected to facilitate the commercialization of these systems in the near future. Collaborative efforts between academia, industry, and regulatory bodies will play a crucial role in translating these innovations into clinical practice.
CONCLUSION
Nanonasal nose-to-brain (N2B) drug delivery has emerged as a highly promising and innovative approach for the management of vestibular disorders, offering a viable alternative to conventional therapeutic strategies. Vestibular conditions such as vertigo, Meniere’s disease, and vestibular neuritis are often associated with significant clinical burden and limitations in treatment due to poor drug penetration across the blood–brain barrier (BBB) and systemic side effects of currently available medications [141]. The unique anatomical and physiological characteristics of the nasal cavity, particularly the presence of olfactory and trigeminal pathways, provide a direct route for drug delivery to the central nervous system (CNS). This enables rapid onset of action, enhanced bioavailability, and reduced systemic exposure, making N2B delivery particularly advantageous for targeting vestibular pathways.The incorporation of nanotechnology into intranasal delivery systems has further enhanced the efficiency of this approach. Nanocarriers such as lipid-based systems, polymeric nanoparticles, and emerging platforms like exosomes offer improved drug solubility, stability, permeability, and controlled release properties. Additionally, advanced formulation strategies including mucoadhesive systems, surface modification, and in situ gels have been shown to overcome nasal barriers and optimize drug delivery.
Extensive in vitro, ex vivo, and in vivo evaluations have demonstrated the potential of nanonasal systems to achieve effective brain targeting, as evidenced by improved drug targeting efficiency (DTE), direct transport percentage (DTP), and favorable biodistribution profiles. Preclinical studies further support their ability to enhance drug accumulation in brain regions associated with vestibular function, highlighting their therapeutic relevance.
However, several challenges remain, including limited dose volume, mucociliary clearance, potential nanoparticle toxicity, and issues related to reproducibility and large-scale manufacturing Regulatory considerations, particularly in terms of safety evaluation and quality control, also play a critical role in the successful clinical translation of these systems.
Looking forward, advancements in smart nanocarriers, stimuli-responsive systems, and nanorobotics hold significant promise for achieving precise and targeted drug delivery. Continued research, along with collaborative efforts between academia, industry, and regulatory authorities, will be essential to overcome existing limitations and facilitate the transition of nanonasal delivery systems from bench to bedside In conclusion, nanonasal N2B delivery represents a cutting-edge therapeutic strategy with the potential to revolutionize the treatment of vestibular disorders. With ongoing innovations and growing scientific evidence, this approach is expected to play a pivotal role in the future of CNS drug delivery and precision medicine.
REFERENCES
Bhavna Awachat, Shilpa Borkar, Jagdish Baheti, Nanonasal Nose-to-Brain Delivery for Vestibular Disorders: Current Status and Future Prospects, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 3481-3500, https://doi.org/10.5281/zenodo.20180610
10.5281/zenodo.20180610
